A previous pilot study demonstrated that EGCG, an inhibitor of dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A), administered to young patients with Down syndrome improved visual recognition memory, working memory performance, and adaptive behavior [104]. Here, DYRK1A is linked to Down syndrome.